



Australian Stock Exchange Limited
ABN 98 008 624 691
Level 3
Stock Exchange Centre
530 Collins Street
Melbourne VIC 3000

GPO Box 1784Q
Melbourne
VIC 3001

Telephone 61 3 9617 8611
Facsimile 61 3 9614 0303
Internet <http://www.asx.com.au>

13 April 2004

Mr Iain Kirkwood
Company Secretary
EpiTan Limited
Level 10
52 Collins St
MELBOURNE

By email

Dear Mr Kirkwood

EpiTan Limited (the “Company”)

RE: PRICE QUERY

We have noted a change in the price of the Company’s securities from 79 cents to 91 cents today. We have also noted an increase in the volume of trading in the securities over this period.

In light of the price change and increase in volume, please respond to each of the following questions.

1. Is the Company aware of any information concerning it that has not been announced which, if known, could be an explanation for recent trading in the securities of the Company?
2. If the answer to question 1 is yes, can an announcement be made immediately? If not, why not and when is it expected that an announcement will be made?

Please note, if the answer to question 1 is yes and an announcement cannot be made immediately, you need to contact us to discuss this and you need to consider a trading halt (see below).

3. Is there any other explanation that the Company may have for the price change and increase in volume in the securities of the Company?
4. Please confirm that the Company is in compliance with the listing rules and, in particular, listing rule 3.1.

Your response should be sent to me by return e-mail or by facsimile on facsimile number 03 9614 0303. It should not be sent to the Company Announcements Office.

Unless the information is required immediately under listing rule 3.1, a response is requested as soon as possible and, in any event, not later than half an hour before the start of trading (ie **before 9.30 a.m. E.S.T.)** on Wednesday, 14 April 2004.

Under listing rule 18.7A, a copy of this query and your response will be released to the market, so your response should be in a suitable form and separately address each of the questions asked. If you have any queries or concerns, please contact me immediately.

Listing rule 3.1

Listing rule 3.1 requires an entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. The exceptions to this requirement are set out in listing rule 3.1A.

In responding to this letter you should consult listing rule 3.1 and Guidance Note 8 – Continuous Disclosure: listing rule 3.1.

If the information requested by this letter is information required to be given to ASX under listing rule 3.1 your obligation is to disclose the information immediately.

Your responsibility under listing rule 3.1 is not confined to, or necessarily satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond by the time requested, or if the answer to question 1 is yes and an announcement cannot be made immediately, you should consider a request for a trading halt in the Company's securities. As set out in listing rule 17.1 and Guidance Note 16 – Trading Halts we may grant a trading halt at your request. We may require the request to be in writing. We are not required to act on your request. You must tell us each of the following.

- The reasons for the trading halt.
- How long you want the trading halt to last.
- The event you expect to happen that will end the trading halt.
- That you are not aware of any reason why the trading halt should not be granted.
- Any other information necessary to inform the market about the trading halt, or that we ask for.

The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. If a trading halt is requested and granted and you are still unable to reply to this letter before the commencement of trading, suspension from quotation would normally be imposed by us from the commencement of trading if not previously requested by you. The same applies if you have requested a trading halt because you are unable to release information to the market, and are still unable to do so before the commencement of trading.

If you have any queries regarding any of the above, please let me know.

Yours sincerely,

Rick Iversen
Senior Companies Advisor



14 April 2004

Rick Iversen
Companies Advisor
Australian Stock Exchange
Level 3, 530 Collins Street,
Melbourne, Victoria 3000

Dear Mr Iversen,

Re: Price Query

I refer to your letter of 13 April and respond to your question items as:

ITEM 1: No

EpiTan (the "Company") made an announcement on 26 March 2004 reporting that, following a comprehensive review of its clinical trial strategy in Europe, it would be substantially expanding its clinical trials for polymorphous light eruption (PMLE) – otherwise known as sun poisoning - during 2004. The company reported that it would be lodging a Clinical Trial Exemption (CTX) application with the European Medicines Evaluation Agency (EMA) to expand the number of PMLE trial sites in Europe to include Great Britain and Sweden.

The Company issued a media release on 25 March 2004 reporting that new research by the Melanoma and Skin Cancer Research Institute at Sydney's Royal Prince Alfred Hospital, indicating that ultraviolet-A light – now found to be a serious cause of skin cancer and which is not blocked out by many sunscreens – represents a further reason to develop and use an Australian drug which produces melanin and which protects against both forms of UV light.

The Company made an announcement on 23 March 2004 reporting that it had appointed former FDA dermatology specialist Dr Ella Toombs as a regulatory advisory consultant. Dr Toombs' prime focus will be to assist the Company prepare its Investigational New Drug (IND) application for Melanotan, which will be submitted to the US Food & Drug Administration in mid-2004.

The Company made a presentation on 11 February 2004 at a Securities Institute of Australia biotech showcase. In this presentation, which was lodged with ASX, it reported it is actively seeking a partnership with a larger pharmaceutical company to assist with bringing Melanotan to market. It also reported it is evaluating expanding

its capital base to the USA or UK to tap apparent investor appetite. These activities are ongoing.

The Company is not aware of any information concerning it that has not been announced which, if known, could be an explanation for recent trading in the securities of the company.

ITEM 3: No

Outside of the statement in item 1 above, the company has no other explanation for the price change and increase in volume in the securities of the company.

ITEM 4: The Company is in compliance with the listing rules and in particular listing rule 3. 1.

Yours sincerely

A handwritten signature in dark ink, appearing to read 'Iain Kirkwood', with a small flourish at the end.

Iain Kirkwood
Company Secretary